Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
killed Mycobacterium leprae vaccine
- Development stage
- Discontinued
- Lead developer
- The London School of Hygiene & Tropical Medicine
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The killed Mycobacterium leprae vaccine is an experimental whole-cell, inactivated bacterial vaccine composed of heat-killed or otherwise inactivated Mycobacterium leprae organisms. It was developed by the London School of Hygiene and Tropical Medicine (LSHTM) and evaluated as part of the Karonga Prevention Trial in northern Malawi. The vaccine was primarily studied in combination with the Bacillus Calmette-Guérin (BCG) vaccine to determine if the addition of killed M. leprae antigens could provide enhanced protection against leprosy and tuberculosis compared to BCG alone or a second dose of BCG. Results from a Phase III randomized, double-blind, placebo-controlled trial indicated that the addition of the killed M. leprae vaccine did not significantly improve protective efficacy over BCG vaccination alone for either leprosy or tuberculosis.
- Other names
- killed M. leprae vaccineinactivated Mycobacterium leprae vaccine
Beyond the preview
Go deeper on killed Mycobacterium leprae vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on killed Mycobacterium leprae vaccine.